Essai Clinique

Généré le 18 mars 2025 à partir de

Titre	A Phase 2, Open-Label, Multicenter Study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Protocole ID	QUINTESSENTIAL
ClinicalTrials.gov ID	NCT06297226
Type(s) de cancer	Myélome
Phase	Phase II
Stade	Récidivant/réfractaire (2ième ligne de traitement et plus)
Type étude	Clinique
Médicament	BMS-986393
Institution	CENTRE UNIVERSITAIRE DE SANTE MCGILL SITE GLEN 1001 boul. Décarie , Montréal, QC, H4A 3J1
Ville	
Investigateur principal	Dr Chaim Shustik Dr Michael Sebag
Coordonnateur	Nancy Renouf 514-934-1934 poste 35718
Statut	Actif en recrutement
But étude	The purpose of this study is to evaluate the effectiveness and safety of BMS-986393 in participants with relapsed or refractory multiple myeloma.
Critères d'éligibilité	• Documented diagnosis of multiple Mmyeloma (MM) as per International Myeloma Working Group (IMWG) criteria. • Received at least 4 classes of MM treatment [including immunomodulatory drug (IMiD), proteasome inhibitor (PI), anti CD38 mAb, and anti-B cell maturation antigen (BCMA) therapy], and at least 3 prior lines of therapy (LOT). • Documented disease progression during or after their last anti-myeloma regimen as per IMWG. • Participants must have measurable disease during screening. • Have measurable disease during screening. • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Critères d'exclusion	• Active or history of central nervous system involvement with MM. • Active systemic fungal, bacterial, viral, or other infection despite appropriate anti-infective treatment at the time of leukapheresis. • Received any prior therapy directed at G protein-coupled receptor class C, group 5, member D (GPRC5D) or has received other prior treatment for MM without the required washout prior to leukapheresis. • Other protocol-defined Inclusion/Exclusion criteria apply.